321329-79-7

Upstream product

• 618-87-1 3, 5-dinitroaniline 
• 321329-77-5 1-(3,5-dinitro-phenyl)-1H-pyrrole 

Downstream Products

• 321329-83-3 C₂₃H₂₅N₃O₄ 
• 1430727-89-1 N-(3-amino-5-pyrrol-1-yl-phenyl)-acetamide 
• 1430727-90-4 N-(3-(4-bromo-2-nitrophenylamino)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430727-91-5 N-(3-(2-amino-4-bromophenylamino)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430727-92-6 N-(3-(5-bromo-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430724-17-6 N-(3-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430727-93-7 3-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)aniline 
• 1430724-18-7 N-(3-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)methanesulfonamide 
• 1430724-21-2 1-(furan-2-ylmethyl)-3-(3-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)urea 
• 1430724-26-7 N-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)-phenyl)acetamide 
• 1430727-94-8 3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)aniline 
• 1430724-27-8 N-(3-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)-phenyl)ethanesulfonamide 
• 1430727-95-9 N-(3-(4-iodo-2-nitrophenylamino)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430727-96-0 N-(3-((2-amino-4-iodophenyl)amino)-5-(1H-pyrrol-1-yl)phenyl)acetamide 

Relevant academic research and scientific papers

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Bradykin B1receptor antagonists

Bradykinin B1-receptor antagonists of formula are disclosed. The compounds are useful for treating diseases associated with inappropriate bradykinin receptor activity, such as diabetic vasculopathy, inflammation, pain, hyperalgesia, asthma, rhinitis, septic shock, atherosclerosis and multiple sclerosis. Pyrimidines, triazines, and anilines in which Q is imidazolyl or pyrrolyl are particularly preferred.